[Ciclopiroxolamine in the topical treatment of vaginal mycoses].
We have verified the local activity and tolerance of the antimycotic drug ciclopiroxolamine in an open trial. The study included 34 women suffering from clinically and mycologically diagnosed vulvovaginitis caused by Candida. The therapy consisted of inserting a 100 mg ovule of ciclopiroxolamine once a day for 3 days. The cultural examination was negative in 76.5% of cases at the 1st control after the treatment and in 82.3% of cases at the 2nd control after the treatment. All the considered subjective and objective symptoms showed a highly significant decrease of frequency and intensity. No chemical parameter was modified; only in one patient a very mild side effect was verified.
A
A
Bucciero
E
E
Molteni
B
B
Molteni
W
W
Mariani
M
M
Jacobellis
D000287:Administration, Topical; D000328:Adult; D000935:Antifungal Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D002181:Candidiasis, Vulvovaginal / Q000188:drug therapy*; D000077768:Ciclopirox; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008875:Middle Aged; D011728:Pyridones / Q000008:administration & dosage* / Q000627:therapeutic use
D000935:Antifungal Agents; D011728:Pyridones; D000077768:Ciclopirox
La ciclopiroxolamina nel trattamento topico delle micosi vaginali.